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Long non-coding RNAs (ncRNAs) have been shown to regulate important biological
processes that support normal cellular functions. Aberrant regulation of these essential
functions can promote tumor development. In this review, we underscore the importance
of the regulatory role played by this distinct class of ncRNAs in cancer-associated pathways
that govern mechanisms such as cell growth, invasion, and metastasis. We also highlight
the possibility of using these unique RNAs as diagnostic and prognostic biomarkers in
malignancies.
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INTRODUCTION
Common knowledge until recently would suggest that only about
1% of the genome produces biologically meaningful RNA tran-
scripts, speciﬁcally those that encode for proteins (Guttman
et al., 2009). In the past decade, however, numerous papers have
appeared that clearly document widespread transcription across
most of the genome. However, the biological relevance of this
transcription has been a matter of much debate, as witnessed by
numerous original peer-reviewed articles, reviews, letters to the
editor, and rebuttals. In particular, van Bakel and Hughes believe
this pervasive transcription is simply transcriptional “noise,”while
Mattick and Kapranov, among others, are of the strong belief these
transcripts are functionally relevant (Kapranov,2009;Mercer et al.,
2009; van Bakel and Hughes, 2009). An in-depth review of pub-
lished data in combination with unpublished observations from
our work in this ﬁeld has led to support the latter interpreta-
tion, based on a strong association of patterns of non-coding RNA
(ncRNA) transcriptionwith diagnosis and prognosis in cancer.We
believe these data can only be interpreted as non-random, biolog-
ically meaningful patterns that point to a general functional role
for ncRNA over much of the genome. Further, the character and
pattern of transcription is itself of considerable interest, as there
is no parallel among annotated, protein-encoding genes for many
of the transcripts we have identiﬁed in several different types of
cancer.
The ﬁndings reported here are consonant with several histori-
cal observations. First, as early as 1980, in a landmark publication,
“The RNA World,” Watson, Crick, and others present compelling
evidence that RNA was the ﬁrst nucleic acid associated with life
on this planet (Atkins et al., 2011). Several lines of evidence con-
verge on the idea that DNA, and subsequently protein-encoding
RNA, only appeared eons later. Prior to that time, RNA subserved
the functions necessary for life currently associated with DNA
(organismalmemory) and protein (enzymatic cleavage, regulation
of transcription, and many others). This “RNA First” hypothesis
is widely accepted now, but the implications for genome-wide
pervasive RNA transcription have only recently garnered atten-
tion. Most students today are still taught the central dogma of
molecular biology, namely that DNA encodes RNA transcripts
that are transcribed from the genome and translated into protein
after cleavage and migration from the nucleus to the cytoplasm,
where the ribosome utilizes the messenger RNA (mRNA) strand
as a speciﬁc template to produce protein. With the vast amounts
and variety of ncRNA transcripts found in every cell at all stages of
development, this central dogma does not fully capture the role of
RNA as a regulatory molecule independent of protein (Pauli et al.,
2011; Suh and Blelloch, 2011).
This review provides evidence that these non-coding tran-
scripts as a group are not only functional, but may well be some
of the most basic and ancient functional RNAs of all. Certainly
they are strikingly different than mRNA, in both structure and
function, yet certain features are shared with mRNA, including, in
some cases, “exons” and “introns,” poly-adenylation, and alternate
splice variants. Conversely, unlike coding genes, ncRNAs occur in
poorly conserved regions of the genome, in stark contrast to the
highly conserved regions associated with coding genes.
Beyond these easily documented features, relatively little is
known about the general structure, function, and transcriptional
control of ncRNAs, and even less about their potential functions
as a group or singly. Unlike coding genes, there is no easily docu-
mented protein product linked to the RNA sequence (Clamp et al.,
2007). However, numerous individual examples have been docu-
mented, with very different structure and function. On the one
hand, H19, a long recognized ncRNA, shows signiﬁcant sequence
conservation and is known to control IGF2 on the opposite pater-
nal chromosome by epigenetic control mechanisms (Feil et al.,
1994; Juan et al., 2000). On the other hand,XIST shows almost no
sequence conservation between species yet consistently silences
one X chromosome in females (Hendrich et al., 1993; Panning
et al., 1997). In yet another well documented example, a ncRNA
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transcribed from the HOX locus, HOTAIR, has been shown to
bind to the polycomb repressor complex 2 (PRC2) and affect
expression of over 300 coding gene targets as part of a general
reprogramming of breast cancer cells from a locally aggressive
epithelial phenotype to an invasive and metastatic “mesenchymal”
phenotype (Gupta et al., 2010). Clearly there are speciﬁc examples
of functional ncRNA. There remains the larger question though
of whether ncRNAs are predominantly functional, and if so, how
this might be determined. In the following examples, we present
evidence that ncRNAs are in fact strongly associated with cancer
diagnosis and prognosis, functions that can hardly be ascribed to
genome-wide random transcription.
CLASSES OF ncRNA TRANSCRIPTION
Non-coding RNAs are an integral part of the mammalian tran-
scriptome. Once described as “dark matter,” these underestimated
molecules can play important functional and structural roles in
the cell (Kapranov et al., 2010; Qureshi and Mehler, 2011). Based
on size, these RNA can be grouped into three major classes: small
ncRNAs, which include microRNA (miRNA), PIWI-interacting
RNA (piRNA), endogenous short interfering RNA (siRNA), and
other non-coding transcripts of less than 200 nucleotides (nt);
long ncRNAs (lncRNA) that are greater than 200 nt and arise from
intergenic regions or are organized aroundprotein-coding regions;
and very long ncRNA (vlncRNA) that can stretch through hun-
dreds of kilobases, often across intergenic regions. While miRNAs
post-transcriptionally regulate mRNA through the RNA-induced
silencing complex, piRNA and siRNA are implicated in maintain-
ing genomic integrity by silencingof transposable elements in cells.
lncRNAs are involved in various levels of genomic regulation and
related fundamental epigenetic processes: genomic imprinting,
dosage compensation, and chromatin modiﬁcations. These can
assist in subcellular transport, recruitment of transcription factors,
and RNA processing and editing by forming ribonucleoprotein
complexes.
CHARACTERISTICS OF ncRNA
POLY-ADENYLATED RNA VERSUS TOTAL RNA TRANSCRIPTION
Non-coding genomic DNA, some of which is genetically func-
tional, has increased proportionally with genomic size and com-
plexity (Taft et al., 2007). The human genome has more “dark
matter” when compared to that of Drosophila. RNA polymerase
II transcribes both protein-coding and non-coding transcripts.
While transcription terminates at a poly-adenylation site for most
protein-coding genes, there is substantial evidence that a frac-
tion of ncRNAs do not necessarily end with a poly-A signal.
This alternate termination of transcripts is sometimes associated
with RNA-binding proteins Nrd1, Nab3, and Sen1 as is seen with
non-poly-adenylated end of small nucleolar RNAs (snoRNAs) in
S. cerevisiae (Creamer et al., 2011). Antisense asOct4-pg5 or the
brain-associated BC200 are examples of functional lncRNA that
are not poly-adenylated (Chen et al., 1997; Hawkins and Morris,
2010). ncRNA comprise approximately 30% of the total poly-A
fraction, while they account for approximately 50–60% of total
RNA with or devoid of ribosomal RNA, thus suggesting that
a signiﬁcant amount of these ncRNAs are non-poly-adenylated
(Kapranov et al., 2010). The lack of poly-A tails has caused these
transcripts to be underrepresented in cDNA libraries, SAGE, dif-
ferential display, and microarrays which typically employ a 3′
poly-A labeling method.
CONSERVED VERSUS NOT CONSERVED
While protein-coding genes are under high constraint, this is not
the case with all ncRNAs. Recent studies have shown the emerging
importance of lncRNAs as regulators of essential cellular functions
that involve a great number of protein interactions (Guttman et al.,
2009). Increased system complexity that enables highly skilled
functions increases evolutionary pressure on regulators of this
dynamic signaling network (Mattick, 2003). These RNAs are pre-
dicted to undergo more rapid evolution than pre-existing proteins
or the de novo evolution of a unique set of signaling molecules
(Ponjavic et al., 2007). Guttman et al. (2010) compared ortholo-
gous sequences of lncRNAs among 29 mammals and showed that
their conservation is far greater than random genomic sequences
or introns. On the other hand, Babak et al. (2005) found poor con-
servation between intergenic genomic transcripts and proposed
that they may thus be non-functional. However, one of the non-
coding elements of the genome, referred to as ultra-conserved
elements (UCEs), is highly conserved. These regions span at least
200 base pairs in length and maintain 100% identity with no
insertions or deletions between human, mouse, and rat genomes
(Bejerano et al., 2004). Other than the exonic components, there
are about 38.7% UCEs that are intergenic while another 42.6% are
intronic (Mestdagh et al., 2010). The average distances observed
among them (approximately 10Mb) suggest that they are unlikely
to function as exons of a gene. Some of these non-coding UCEs
are transcribed (T-UCEs) and maintain evolutionary constraints.
FUNCTIONAL VERSUS NON-FUNCTIONAL
Less than 1% of lncRNAs have been associated with a function.
Their cell- and tissue-speciﬁc expression that changes in response
to external factors such as stress and other environmental signals
implies that their presence is dependent on the need of the cell.
Many of these lncRNAs have binding sites for transcription fac-
tors Sp1, c-Myc, p53, and Creb, thus suggesting different levels
of regulation (Cawley et al., 2004; Euskirchen et al., 2004). Their
involvement varies from transcriptional to post-transcriptional
regulation to translational control. There is evidence that some of
these are essential for development (Rosenbluh et al., 2011; Han
et al., 2012). For example, Mirg, a maternal ncRNA from the Dlk–
Dio3 imprinted cluster, is expressed in different tissues at different
time during murine embryonic development (Han et al., 2012).
GENERAL PATTERNS OF ncRNA EXPRESSION IN NORMAL
TISSUES AND CANCER
The concept of a functional genome is being rewritten with the
discovery of ncRNA. The abundance of these transcripts in cancer
suggests their role in tumor pathogenesis. ncRNAs are abundant
during embryogenesis (van Leeuwen and Mikkers, 2010; Pauli
et al., 2011) and reactivation or non-suppression of some of these
fetal lncRNAs may critically regulate pluripotency and uninhib-
ited cellular growth, thus giving rise to adult or developmental
cancers. For example, the H19 lncRNA is expressed during ver-
tebrate embryogenesis but is downregulated after birth in most
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tissues except for cartilage and skeletal muscle (Lustig et al., 1994).
However, loss of imprinting and overexpression of H19 in many
cancers such as those of esophagus, liver, colon, and bladder cause
it to function as an oncogene and promote tumor development
(Hibi et al., 1996; Barsyte-Lovejoy et al., 2006;Matouk et al., 2007).
Similarly, normal adult tissues express lncRNAs at various levels
with lymph nodes and gall bladder reportedly having themost dis-
tinct lncRNAs (Gibb et al., 2011). Comparisons between normal
and cancerous tissues revealed differential expression of at least
200 lncRNAs. The chromosome distribution of lncRNAs did not
correlate with either protein-coding genes or miRNAs. Kapranov
et al. (2010) also showed that in Ewing sarcoma, a childhood can-
cer, 43–63% of all non-ribosomal, non-mitochondrial RNAs by
mass were non-exonic RNAs, and 24–37% of these were detected
in intergenic regions. This study also suggested the presence of
a vlncRNA of approximately 650 kb on chromosome 7 that was
exclusively present in Ewing sarcoma and not in the leukemia cell
line K562, normal brain, or liver. Similarly, another 300 kb inter-
genic region on chromosome 21 in the K562 cell line was not
detected in Ewing sarcoma, suggesting that certain ncRNAs may
be present in speciﬁc cancers.
ROLE OF ncRNAs IN TUMOR PATHOGENESIS: ONCOGENES
OR TUMOR SUPPRESSORS
ncRNAs have been detected in cancer by various techniques
including expression microarrays, tiling arrays, next generation
sequencing, and methylation analysis (Cheung et al., 2010; Gupta
et al., 2010; Sang et al., 2010; Trapnell et al., 2010). These
approaches have led to the identiﬁcation of several lncRNAswhose
expression and epigenetic state are signiﬁcantly associated with
cancerous tissues.
Like protein-coding genes, ncRNAs may function as tumor
oncogenes or tumor suppressors. Some T-UCEs are frequently
located at fragile sites and cancer-associated genomic regions
(CAGRs) such as minimal regions of ampliﬁcation and of loss of
heterozygosity, while others are known to act as oncogenes in can-
cer cells (Rossi et al., 2008). Functional analysis involving siRNAs
identiﬁed uc.73A as a promoter of cell survival by evading cellu-
lar apoptosis in colorectal cancer (Calin et al., 2007). Enrichment
analyses conﬁrmed that UCEs are contained in genes involved in
RNA processing and RNA binding (Licastro et al., 2010). They
bear resemblance to enhancer-like sequences and are involved in
transcription.
Protein-coding genes are known to be associated with antisense
transcripts, and perturbation of these can alter protein expression
that promotes cancer development (He et al., 2008). Antisense
transcriptsANRIL and p21/CDKN1A-associated transcript repress
tumor suppressor loci and promote cancer (Morris et al., 2008).
Aberrant gene expression causes changes in chromatin structure
leading to genomic instability that can give rise to uncontrollable
growth and an invasive cellular phenotype. Therefore, proteins
that control chromatin organization including polycomb repres-
sor complexes, PRC1 and PRC2, and members of the trithorax
family constitute key players in the molecular pathogenesis of
cancer. Selective binding of lncRNAs, HOTAIR and ANRIL, with
PRC1 and PRC2 to execute histone modiﬁcations at speciﬁc loci
thus strongly supports the idea that lncRNAs may function as
ideal regulators for epigenetic transcriptional repression (Gupta
et al., 2010; Kotake et al., 2011). ANRIL and associated fac-
tors play critical roles in repression of the INK4b–ARF–INK4a
locus that encodes for three critical tumor suppressors, p15INK4b,
p14ARF (p19ARF in mice), and p16INK4a, which play central roles
in cell-cycle inhibition, senescence, and stress-induced apoptosis
(Pasmant et al., 2007; Yap et al., 2010; Kotake et al., 2011).
Long ncRNAs may also act as tumor suppressors. They may
inhibit cell-cycle progression in response to DNA damage due to
stress and environmental factors. lncRNAncRNACCND1 is induced
during DNA damage from the CCND1 promoter (Wang et al.,
2008). This lncRNA recruits the TLS protein to the CCND1 pro-
moter where it binds to histone acetyltransferases CBP/p300 and
in turn inhibitsCCND1 transcription thus affecting cell-cycle pro-
gression. Some lncRNAsmay inhibit growth in cancer cells.MEG3,
a lncRNA that is expressed in many normal tissues but not in
human cancer cell lines, may function as a tumor suppressor as its
ectopic expression in cancer cells suppressed their growth (Zhang
et al., 2003).
ASSOCIATIONS OF lncRNAs WITH CANCER
Genome-wide association studies of cancer susceptibility have
identiﬁed single nucleotide polymorphisms (SNPs) in some of
the transcribed regions of the non-coding portions of the human
genome (Manolio et al., 2008). T-UCEs differentially expressed in
human cancers are located in CAGRs that are speciﬁcally asso-
ciated with that type of cancer (Calin et al., 2007). These could
be candidate players for cancer susceptibility. For example, dif-
ferential expressions of uc.349A and uc.352 between normal and
leukemic CD5-positive cells have been linked to susceptibility to
familial chronic lymphocytic leukemia (Ng et al., 2007).Consistent
with these ﬁndings,Yang et al. (2008) have reported that two SNPs
in UCEs (rs9572903 and rs2056116) are associated with famil-
ial breast cancer risk. Recently, Pasmant et al. (2011) have also
shown that modulation of ANRIL levels in patients with neuroﬁ-
bromatosis mediates susceptibility to plexiform neuroﬁbromas.
SNP rs2151280 located in ANRIL locus was statistically signif-
icantly associated with number of plexiform neuroﬁbromas in
these patients.
ncRNAs AND CANCER DIAGNOSIS
The differences in lncRNA proﬁling between normal and cancer
cells may or may not be a mere secondary effect of cancer-
ous transformations. Several lncRNAs can control transcriptional
alteration, as seen with ANRIL and its interaction with PRC pro-
teins that leads to repression of INK4b locus, a change observed in
most cancers (Kotake et al., 2011). In other cases, altered expres-
sion of these RNAs may show a strong association with tumor
progression, and thus can be used as classiﬁcation markers for
these malignancies. Most lncRNAs are expressed in various types
of cancers; however, somehave been associatedwith speciﬁc tumor
types. A striking example is that of three lncRNAs in prostate
cancer: PCGEM1, DD3, and PCNCR1 (Bussemakers et al., 1999;
Petrovics et al., 2004; Chung et al., 2011). These lncRNAs either
promote tumorigenicity or are associated with susceptibility to
prostate adenocarcinoma. These unique lncRNAs could therefore
potentially be used for prostate cancer diagnosis. The malignant
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cells have a unique spectrum of expressed UCEs when compared
with the corresponding normal cells, suggesting that variations in
T-UCE expression are involved in the malignant process. More-
over, distinct T-UCE signatures were differentially expressed in
leukemias and carcinomas, and thus may offer a novel strategy for
cancer diagnosis and prognosis (Calin et al., 2007).
Our experience with childhood tumors have led us to believe
that ncRNAs play key roles in deﬁning tumor subtypes (Bajaj
et al., 2011). We have performed several exploratory analyses in
pediatric tumors that provide evidence of unique non-coding
intergenic regions that are characteristic of tumor types. One
such preliminary analysis depicted in Figure 1 involved 40 unique
primary tumors from patients with PAX–FKHR fusion-positive
rhabdomyosarcoma (n = 10), fusion-negative rhabdomyosar-
coma (n = 10),Ewing family of tumors (EFT,n = 5),osteosarcoma
(n = 5), neuroblastoma (n = 5), and Wilms’ tumors (n = 5). An
unsupervised nearest shrunken centroid model, a class predic-
tion procedure that identiﬁes transcripts that best characterize
tumor subtypes, was used to analyze whole-transcriptome expres-
sion proﬁling data obtained from these tumors using Affymetrix
Human Exon 1.0 ST microarrays. This procedure eliminates clas-
siﬁer transcripts from the prediction signature as the shrinkage
parameter (Δ) increases, thereby creating highly class-speciﬁc pro-
ﬁles (Tibshirani et al., 2002). This revealed the presence of several
classiﬁer coding and non-coding transcripts, represented as probe
set regions (PSRs) on the top histogram of Figure 1A, that were
able to categorize tumors in the training (aqua line) and test (gold
line) sets with 100 and 95% accuracy at Δ= 5.6, respectively.
Examination of features contained in the centroid classes revealed
the presence of a 250-kb stretch of non-coding transcript (locus
marked by dashed black box in Figure 1C), a putative vlncRNA,
which was unique to EFTs (tumor class 3 in Figure 1C). This
tumor subgroup uniquely showed marked overexpression of this
genomic stretch that does not code for any known proteins (aqua
trace in Figure 1D); none of the other childhood tumors examined
in this cohort appeared to express this vlncRNA at levels compara-
ble to EFT. This demonstrates that the presence of such transcripts,
if found on a larger scale with similar discriminatory power, may
be extremely helpful in diagnosing such tumor types. In addition,
it also suggests that such non-coding transcripts may play a role
in the genesis and maintenance of these malignancies.
ncRNAs AND CANCER PROGNOSIS
Differential expressions of protein-coding genes and small ncR-
NAs between cancers have been used as a valuable tool to generate
signatures that can reliably predict disease outcomes (Martens-
Uzunova et al., 2012). A panel of 10 biomarkers that included
8 protein-coding genes and 2 miRNAs, miR-519d and miR-647,
could signiﬁcantly predict clinical recurrence in prostate cancer
following radical prostatectomy (Long et al., 2011).
With recent growing evidence of similar expression patterns of
lncRNAs in cancers, these transcriptsmay be proﬁled as prognostic
candidates. A similar strategy may be adopted to develop lncRNA-
dependent gene signatures that may predict disease outcomes
and response to treatments. The lncRNA MALAT1 is upregulated
in many solid tumors and is associated with cancer metasta-
sis and recurrence. In hepatocellular carcinoma, MALAT1 levels
corresponded to advanced disease stage and were inversely related
to disease-free survival after liver transplantation (Lai et al., 2012).
Similarly, an expression proﬁle based on 28 T-UCEs in 14 patients
with neuroblastoma was able to signiﬁcantly distinguish between
short-term and long-term survivors (Scarufﬁ et al., 2009).
Our group’s efforts in identifying non-coding transcripts
that are associated with outcome have focused on childhood
tumors. In one such analysis shown in Figure 2, we initially
analyzed Affymetrix Human Exon 1.0 ST array-derived whole-
transcriptome expression proﬁling data on primary EFT samples
from 40 patients at surgical resection with long subsequent follow-
up. Thirteen (32.5%) patients eventuallymetastasized (depicted in
red in Figures 2A–D). An unsupervised nearest shrunken centroid
model was used to identify coding and non-coding features that
could categorize these tumors based on their probability of even-
tually metastasizing. At Δ= 1.2, several features were identiﬁed
that could categorize the tumors into two groups based on risk of
metastasis with 92.5 and 70% accuracies in the training and test
sets, respectively (Figure 2A).
To further investigate the biological implications of ncRNA
features that could predict tumor metastasis, expression proﬁles
on two EFT cell lines, CHLA-9 and CHLA-10, were analyzed
using a similar nearest shrunken centroid model. At Δ= 6.0,
the selected features were able to classify samples in the train-
ing and test sets with 100% accuracy (Figure 2C). When this
set of classiﬁer features was compared to those obtained from
the analysis of the above EFT samples, a unique 26 kb intergenic
non-coding transcript was identiﬁed on chromosome 2 (dashed
black box in Figures 2B,D). The expression of this transcript was
seemingly protective in nature – its expression was highest in pri-
mary tumors that did not metastasize, and lower in those primary
tumors that eventually metastasized (Figure 2E). Following this
trend, its expression was comparably lower in CHLA-9, a cell line
generated from the primary tumor of an EFT patient, and lowest
in CHLA-10, a cell line generated from a subsequent metastatic
tumor in the same patient (Batra et al., 2004). Such observations
provide credence to the argument that non-coding transcripts play
crucial roles in the modulation of tumor behavior and can be used
as markers in the primary malignancy to determine long-term
prognosis.
ncRNAs: BRIDGING NORMAL TISSUE DEVELOPMENT AND
ONCOGENESIS
The data and studies presented here offer compelling evidence that
transcription of ncRNAs in cancer is tightly linked to key biologi-
cal processes, from differentiation to metastasis. The parallel with
normal tissue differentiation during fetal development is strik-
ing and reminiscent of another well documented phenomenon in
cancer: to reprise the expression of fetal antigens during oncogen-
esis. Given the documented higher levels of ncRNA transcription
during normal tissue development, it should be no surprise that
ncRNA levels in cancer are elevated compared to normal tissue
development. Many parallels between oncogenesis and develop-
ment are well known, such that oncogenesis is often viewed as a
poorly executed mimicry of normal tissue development. Environ-
mental inﬂuences may allow embryonic expression of lncRNAs in
adult tissues that alter gene expression, thereby increasing cancer
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FIGURE 1 | Nearest shrunken centroid analysis to identify a putative
EFT-specific vlncRNA. (A) Nearest shrunken centroid modeling was
performed on 40 unique primary childhood tumors. Shrinkage parameter
(X -axis) Δ= 5.6 was selected as the threshold where the fewest number of
PSRs (Y -axis, top panel) were required to categorize tumors in the training
(aqua line) and test (gold line) sets with 0 and 5% error, respectively (Y -axis,
bottom panel). (B) Classiﬁcation performance of training set samples is
shown, where probability of samples belonging to each color-coded tumor
class (1, PAX –FKHR fusion-positive rhabdomyosarcoma; 2, fusion-negative
rhabdomyosarcoma; 3, EFT; 4, osteosarcoma; 5, neuroblastoma; 6,Wilms’
tumors) was predicted with 100% accuracy at Δ= 5.6. Note that only squares
of the like color are found at the 100% probability level in each true class. (C)
Whole-genome plot of positions of the diagnostic PSRs (X -axis) that
characterize the respective tumor groups versus their expression levels
(Y -axis). A 250-kb stretch corresponding to a putative vlncRNA region (dashed
black box) was observed as being uniquely overexpressed in EFT. (D)When
zoomed in at this genomic segment (blue arrow points to the RefSeq
annotation; red arrow indicates positions of PSRs across the region),
evidence of signiﬁcant overexpression of this transcript in EFTs (aqua trace)
was clear compared to other childhood tumor types. Height of theY -axis
corresponds to the logarithm of PSR expression levels, and samples are
aggregated into their respective tumor groups.
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FIGURE 2 | Identification of a non-coding transcript showing differential
expression in EFTs with respect to metastasis. (A) Classiﬁcation
performance of a nearest shrunken centroid model is shown, where 40
primary EFTs were categorized based on their eventual metastatic fate
(green, did not metastasize; red, eventually metastasized) in the training set
with 92.5% accuracy at Δ= 1.2. (B) PSRs identiﬁed by this analysis that
distinguish between non-metastasized versus metastasized groups are
plotted over a whole-genome sequence, where height of theY -axis over and
under the baseline corresponds to their log fold change. (C) A similar nearest
shrunken centroid analysis on CHLA-9 and CHLA-10 achieved 100%
classiﬁcation accuracy at Δ= 6.0. (D) Comparing the PSR proﬁles between
both nearest shrunken centroid models resulted in the identiﬁcation of a
common 26 kb intergenic non-coding transcript [dashed black box in (B) and
(D)]. (E) A zoomed in inspection of this genomic segment (blue arrow points
to the RefSeq annotation; red arrow indicates positions of PSRs across the
region) showed that the transcript was highly expressed in tumors that never
metastasized, moderately expressed in tumors that eventually metastasized
and CHLA-9, and showed low expression in CHLA-10. Height of theY -axis
corresponds to the logarithm of PSR expression levels, and samples are
aggregated into their respective tumor groups.
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susceptibility. The chromatin-interacting ncRNA KCNQ1OT1
causes imprinting of CDKN1C gene in embryonic tissues (Lewis
et al., 2004). CDKN1C gene expression is suppressed in breast
cancers by estrogen through epigenetic mechanisms involving the
highly expressed KCNQ1OT1 gene (Rodriguez et al., 2011). It is
therefore not unreasonable to deduce that ncRNA expression is
of fundamental importance, to the extent that ncRNA expres-
sion may well control coding RNA expression, using the latter
to execute complex and fundamental programs responsible for
organismal development. From a combined viewpoint, therefore,
ncRNA is primary and coding RNA is secondary. The fact that a
ncRNA gene like HOTAIR can orchestrate the expression of over
300 coding genes via complex formationwith PRC2 and epigenetic
regulation, leading to altered tumor cell differentiation and behav-
ior, is entirely consistent with this concept. It will not be surprising,
therefore, if a general pattern of ncRNA control of coding gene
expression emerges from the many current studies on ncRNAs.
Beyond simple primary–secondary control mechanisms, it also
appears that ncRNA itself is likely tightly regulated in an interac-
tive network (Sumazin et al., 2011). This model of self-regulating
RNA networks is intuitively attractive, as it allows for a degree of
subtle control via multiple interacting regulatory networks that
is essential to account for the development of higher organisms
such as humans. The observation that ncRNA expression levels
are highest in developing brain is consonant with this concept.
The challenge going forward will be to unravel and understand
these complex interactions. The reward will almost certainly be a
far more sophisticated understanding of how biology works, and
by extension, how it is perturbed in cancer.
CONCLUSION
This review provides some evidence of the multifaceted roles of
lncRNAs in cancer. It underscores the importance of the func-
tional existence of these transcripts that are proving to be much
more than “transcriptional noise.”Understanding their biological
relevance in normal developmentmayprovide an insight into their
perturbed functions in cancer. This will allow use of these enig-
matic molecules as diagnostic or predictive biomarkers. They may
be further developed into cancer-speciﬁc RNA targets to improve
treatment sensitivity for various malignancies.
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